J&J’s Shockwave deal pays off as IVL catheter meets primary endpoint in trial

Johnson & Johnson’s (J&J) Shockwave Medical unit has reported that its Javelin peripheral intravascular lithotripsy (IVL) catheter system successfully met the primary endpoints in a clinical trial, demonstrating both safety and efficacy for treating patients with peripheral artery disease (PAD).